Improved respiratory syncytial virus fusion F protein mutant and its application
By designing the modified RSV F protein mutant, using its own soluble expression region fragment to replace the C-terminal transmembrane region and introducing inter-chain disulfide bond mutation, the problem of poor immune protection in existing RSV vaccines is solved, and the Without the introduction of the heterotrimerization domain, the trimer structural stability and immunogenicity of the RSV F protein are enhanced, providing continuous immune protection.
Patent Information
- Application Number
- CN202311774986.3
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2023-12-21
- Publication Date
- 2024-11-26
- Estimated Expiration
- 2043-12-21
AI Technical Summary
Among the existing RSV vaccines, which use pre-fusion conformation F protein as the antigen, have the problem of poor long-lasting protection after immunity, especially the decrease in the immune protection rate in the second epidemic season, and due to the use of heterotrimerization domains This leads to pre-existing immunity and makes it difficult to provide continuous protection through repeated vaccination.
Design an improved respiratory syncytial virus fusion F protein mutant, replaces the C-terminal transmembrane insoluble region by intercepting structural rigid fragments of its own soluble expression region, and introduces inter-chain disulfide bond mutations to ensure that the protein does not introduce heterogeneity. In the case of the source trimerization domain, a stable trimer structure is formed, maintaining the pre-fusion conformation, and enhancing protein stability and immunogenicity.
The trimer structural stability and immunogenicity of RSV F protein mutants are achieved without introducing a heterotrimerization domain, which can be expressed at a large scale in mammalian cells, inducing high levels of Neutralizing antibodies provide continuous immune protection, avoid pre-existing immunity, and improve the durability and protective effect of the vaccine.
Smart Images

Figure CN117886902B_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the field of biomedicine technology, and in particular to an improved respiratory syncytial virus fusion F protein mutant and application thereof. Background Art
[0002] Respiratory Syncytial Virus (RSV) is a common respiratory virus. Infected cells fuse together to form a large cell structure similar to a "syncytium". The clinical manifestation of infection is upper respiratory tract disease, which can further develop into lower respiratory tract disease. It is an important viral pathogen that causes acute lower respiratory tract infection (ALRI) in infants, the elderly, and immunocompromised adults. In young children, the manifestations of RSV infection include bronchiolitis, pneumonia, and tracheobronchitis. The elderly and immunocompromised adults will experience more severe manifestations of infection, including bronchiolitis, pneumonia and asthma, exacerbation of chronic obstructive pulmonary disease, or exacerbation of congestive heart failure.
[0003] RSV infection is mainly mediated by transmembrane envelope glycoproteins F and G. Although both F and G proteins are outside the viral envelope and have multiple specific antigenic determinants, the F sequence is highly conserved between different subtypes. Vaccines using F protein as an antigen are expected to stimulate the body to produce a broader spectrum of protection, making F protein an important candidate antigen for RSV vaccines. During the period of mediating the fusion of the viral envelope and the host cell membrane, the F protein changes from a metastable pre-fusion conformation to a stable post-fusion conformation. A large amount of preclinical and clinical data show that vaccines with prefusion conformation RSV F as antigen can stimulate the body to produce higher levels of virus neutralizing antibodies (Griffin, MR (2022). "A Challenge to Respiratory Syncytial Virus Illness in Adults." N Engl J Med 386 (25): 2427-2428.), but the prefusion conformation F protein is easily converted to the postfusion conformation after physical or chemical stress or storage (McLellan, JS, et al. (2013). "Structure-based design of a fusion glycoprotein vaccine for respiratory syncytial virus." Science 342 (6158): 592-598.), so the F protein needs to be designed to maintain the stability of the prefusion conformation.
[0004] At present, two preventive RSV vaccines, Arexvy and Abrysvo, which use the prefusion conformation F protein as an antigen, have been approved for marketing internationally, but no related preventive vaccine products have been approved for marketing in China. Arexvy was developed by GSK and is composed of the prefusion conformation F protein and the adjuvant system 01 (AS01E). Abrysvo was developed by Pfizer and is composed of the bivalent prefusion conformation F protein as an antigen. Both vaccines are only used in the United States for people aged 60 and above. However, both Arexvy and Abrysvo vaccines have the problem of unsatisfactory long-term protection after immunization. According to reports, the immunization protection rates of the two vaccines in the first epidemic season were 66.7% (LRTD2+) and 82.6% (LRTD), respectively, and the immunization protection rates in the second epidemic season dropped to 48.9% (LRTD2+) and 56.1% (LRTD), respectively, and the booster vaccination in the second epidemic season failed to improve the immunization protection rate.
[0005] In order to express the protein in a soluble form and maintain the trimerized conformation, the antigen design of Arexvy and Abrysvo vaccines both use a heterologous trimerization domain foldon to replace the C-terminal transmembrane insoluble region. However, the use of a heterologous trimerization domain is prone to pre-existing immunity, and it is difficult to provide sustained protection through repeated vaccinations when the vaccine immunity is not ideal. Therefore, we are committed to designing a modified pre-fusion conformation respiratory syncytial virus F protein without the introduction of a heterologous trimerization domain, in order to provide sustained immune protection for the body. Summary of the invention
[0006] In order to solve the above problems, the present invention provides a modified respiratory syncytial virus fusion F protein mutant, which can stably present a trimerization conformation without introducing a heterologous trimerization domain, thereby ensuring that the protein is similar to the natural conformation, providing a new direction for clinical application, and laying the foundation for the development of new products to prevent and block RSV infection.
[0007] The present invention focuses on the research of respiratory syncytial virus fusion F protein. Based on the guidance of structural biology and bioinformatics, a specific mutant that can stably present a pre-fusion conformation is designed. Compared with the wild-type F protein, the RSV F protein mutant can form a trimer structure without introducing a heterologous trimerization domain, and further design mutations to maintain it in a relatively stable fusion precursor state. The target protein can be expressed in a large-scale soluble manner using mammalian cells, and the protein stability performance is excellent. When it is used as a vaccine or vaccine component, its immunogenicity is enhanced, and it can induce immunized animals to produce higher neutralizing antibody levels. The RSV F protein mutant described in this application can be used to prevent and / or treat RSV infection, and can also be used as a detection reagent for respiratory syncytial virus. The mutant can be used alone when used to prevent and / or treat RSV infection, can be used with different adjuvants to form a vaccine composition, and can also be used with different types of vaccine products to form a multi-vaccine.
[0008] The first object of the present invention is to provide an improved respiratory syncytial virus fusion F protein mutant, wherein the mutant uses a fragment of the respiratory syncytial virus fusion F protein's own soluble expression region to replace the C-terminal transmembrane insoluble region of the respiratory syncytial virus fusion F protein.
[0009] Furthermore, a segment of the respiratory syncytial virus fusion F protein's own soluble expression region is a segment with rigid structure.
[0010] In the present invention, a structurally rigid fragment of the RSV fusion F protein's own soluble expression region is intercepted to replace its C-terminal transmembrane insoluble region, which not only achieves the soluble expression of the target protein, but also can present a trimerization conformation without introducing any heterologous trimerization domain, thereby ensuring that the protein is similar to the natural conformation, and thus can avoid the body's pre-existing immunity when it is used as a vaccine component.
[0011] Furthermore, the amino acid sequence of the respiratory syncytial virus fusion F protein is as shown in SEQ ID NO.1, and a fragment of the soluble expression region of the respiratory syncytial virus fusion F protein itself is an amino acid sequence fragment from positions 155 to 173, an amino acid sequence fragment from positions 190 to 204, or an amino acid sequence fragment from positions 255 to 275 of the amino acid sequence shown in SEQ ID NO.1.
[0012] Furthermore, the C-terminal transmembrane insoluble region of the respiratory syncytial virus fusion F protein is the amino acid fragment at position 510 and thereafter of the amino acid sequence shown in SEQ ID NO.1.
[0013] Furthermore, when performing the replacement of the amino acid fragment at position 510 and thereafter, it also includes mutating the lysine at position 508 and the serine at position 509 to cysteine (K508C-S509C).
[0014] In the present invention, the structural rigid fragment of the self-soluble expression region is a non-trimeric conformation in the natural state. In order to further increase the interaction force between trimers, the K508C-S509C mutation adjacent to the C-terminus is further introduced. The introduction of the interchain disulfide bond can increase the interaction between the C-termini of the trimers and is included in the C-terminal design modification.
[0015] Furthermore, the mutant also includes at least one disulfide bond mutation.
[0016] In the present invention, since there are no interchain disulfide bonds between the wild-type respiratory syncytial virus fusion F protein trimers, the mutation design of the interchain disulfide bonds can further improve the trimer stability.
[0017] Furthermore, the mutant is obtained by subjecting the amino acid sequence of SEQ ID NO.1 to at least one of the following mutations:
[0018] The alanine at position 74 and the glutamic acid at position 218 were mutated to cysteine (A74C, E218C);
[0019] The glutamine at position 279 and the alanine at position 241 were mutated to cysteine (Q279C-A241C).
[0020] Furthermore, the mutant also includes mutating one or more charged amino acids in the amino acid sequence of the respiratory syncytial virus fusion F protein into polar amino acids, hydrophobic amino acids or aromatic amino acids to release the electrostatic repulsion in the RSV F protein and enhance the stability of the RSV F pre-fusion protein.
[0021] Furthermore, the mutant is obtained by subjecting the amino acid sequence of SEQ ID NO.1 to at least one of the following mutations:
[0022] The glutamic acid at position 60 was mutated to alanine (E60A), glycine (E60G), serine (E60S), threonine (E60T), leucine (E60L), methionine (E60M), or phenylalanine (E60F).
[0023] Furthermore, the mutant also includes deleting a fragment containing a flavidin protease cleavage site in the amino acid sequence of the respiratory syncytial virus fusion F protein.
[0024] In the present invention, the fragment containing the feline protease cleavage site is deleted, which can avoid the breakage caused by feline protease cleavage in the wild-type RSV F protein, thereby maintaining the pre-fusion conformation of the F protein. In the present invention, no site-directed mutagenesis of any feline protease cleavage site is introduced, and no heterologous connection sequence is required, so a higher sequence similarity can be maintained compared with the wild-type sequence.
[0025] Furthermore, the mutant is obtained by deleting 28 to 46 amino acids between positions 100 and 147 in the amino acid sequence shown in SEQ ID NO.1.
[0026] Furthermore, the mutant is obtained by deleting 37 amino acids between positions 105 and 143 in the amino acid sequence of SEQ ID NO.1 (loss of 37 amino acids between positions 105 and 143).
[0027] The second object of the present invention is to provide a nucleic acid molecule encoding the respiratory syncytial virus fusion F protein mutant.
[0028] Further, the nucleic acid molecule has been codon optimized for expression in mammalian cells.
[0029] The third object of the present invention is to provide a vector, which comprises the nucleic acid molecule.
[0030] The fourth object of the present invention is to provide a cell, wherein the cell expresses the respiratory syncytial virus fusion F protein mutant, or comprises the nucleic acid molecule, or comprises the vector.
[0031] The fifth object of the present invention is to provide a vaccine, which comprises the respiratory syncytial virus fusion F protein mutant.
[0032] Furthermore, the vaccine also contains other active ingredients.
[0033] Furthermore, the vaccine also contains a vaccine adjuvant.
[0034] The sixth object of the present invention is to provide a pharmaceutical composition, which comprises the respiratory syncytial virus fusion F protein mutant, the vaccine, the nucleic acid molecule or the vector.
[0035] Furthermore, the pharmaceutical composition includes pharmaceutically acceptable excipients.
[0036] Furthermore, the pharmaceutically acceptable excipients include protective agents, stabilizers, preservatives, bactericides, inactivators, adjuvants and / or buffers.
[0037] The seventh object of the present invention is to provide the use of the respiratory syncytial virus fusion F protein mutant, the nucleic acid molecule, the vector, the cell, the vaccine or the pharmaceutical composition in the preparation of products for detecting, preventing and / or treating respiratory syncytial virus infection.
[0038] By means of the above scheme, the present invention has at least the following advantages:
[0039] The present application provides a designed and improved respiratory syncytial virus fusion F protein mutant, in which the C-terminus of the RSV F protein mutant uses a fragment of the F protein's own soluble expression region to replace the C-terminal transmembrane insoluble region of the F protein, which not only achieves the ability to use mammalian cells for large-scale soluble expression of the target protein, but also can form a trimer structure without using a heterologous trimerization domain, avoiding the defect of the prior art in which the F protein produces pre-existing immunity when used as a vaccine component due to the introduction of a heterologous trimerization domain.
[0040] In addition, the present application further maintains the respiratory syncytial virus fusion F protein in a relatively stable fusion precursor state by designing mutations, and the protein stability performance is excellent. The designed mutants are immunogenic when used as vaccines or vaccine components, and can induce immunized animals to produce higher neutralizing antibody levels. The RSV F protein mutants described in the present application can be used to prepare recombinant protein RSV vaccines to prevent and treat diseases and conditions caused or mediated by RSV.
[0041] The above description is only an overview of the technical solution and some results of the present invention. In order to more clearly understand the technical means of the present invention and implement it according to the contents of the specification, the preferred embodiments of the present invention are described as follows with detailed drawings. BRIEF DESCRIPTION OF THE DRAWINGS
[0042] Figure 1 , a template amino acid sequence for constructing the RSV F protein mutant described in certain embodiments; the template amino acid sequence includes a heterologous signal peptide sequence "MKWVTFLLLLFISGSAFS" (underlined), an F2 polypeptide (residues 26-109), "|……|" indicating the deletion of 37 amino acids between positions 105 and 143, an F1 polypeptide (residues 143-509), and a replacement sequence (shown in black bold font, residues 155-173); the amino acid positions are the corresponding positions relative to the wild-type RSV F sequence described in SEQ ID NO.1;
[0043] Figure 2 , the F protein expression was measured using the pre-fusion F protein specific recognition antibodies D25 and AM14, where SC-TM, DS-CavI, and pXCS847 were positive controls;
[0044] Figure 3 , F protein stability was determined using antibodies D25 and AM14 that specifically recognize the pre-fusion F protein, with SC-TM, DS-CavI, and pXCS847 as positive controls;
[0045] Figure 4 , sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) analysis of the purified protein of fusion F protein mutant YK001Ag399 under reducing (R) and non-reducing (NR) conditions;
[0046] Figure 5 , SEC analysis of purified F proteins of fusion F protein mutant YK001Ag399 and control molecules SC-TM, DS-CavI, and pXCS847;
[0047] Figure 6 , the immunogenicity (binding antibody) evaluation results of the vaccine composition prepared with the fusion F protein mutant YK001Ag399 as the core component. DETAILED DESCRIPTION
[0048] The present invention discloses improved respiratory syncytial virus prefusion F protein mutants and their applications. Those skilled in the art can refer to the content of this article and appropriately improve the process parameters to achieve it. It is particularly important to point out that all similar replacements and modifications are obvious to those skilled in the art, and they are all considered to be included in the present invention. The methods and applications of the present invention have been described through preferred embodiments, and relevant personnel can obviously modify or appropriately change and combine the methods and applications described herein without departing from the content, spirit and scope of the present invention to implement and apply the technology of the present invention.
[0049] the term:
[0050] In the present application, the term "respiratory syncytial virus" or "RSV" belongs to the genus Pneumovirus of the family Paramyxoviridae. The virus is usually an important viral pathogen that causes acute lower respiratory tract infection (ALRI) in infants, the elderly and immunocompromised adults, and can cause interstitial pneumonia and bronchiolitis.
[0051] In the present application, the term "protein mutant" may generally refer to a protein whose amino acid sequence or protein structure has one or more changes compared to the wild-type protein. The changes may include: deletion, insertion, substitution, truncation and / or deletion of one or more amino acids, processing or cutting of the protein structure. In the present application, protein mutant refers to respiratory syncytial virus (RSV) F protein mutant.
[0052] In the present application, the term "amino acid mutation" generally refers to the modification of an amino acid in a parent amino acid sequence. For example, the modification may include replacement, insertion and / or deletion of one or more amino acids. In the present application, the amino acid mutation may include deletion or replacement of at least one amino acid residue at a specified position of an amino acid sequence. In certain embodiments, the amino acid mutation can optimize the conformation of a protein composed of the amino acid sequence. Amino acid mutations may be produced using genetic or chemical methods well known in the art. For example, genetic methods may include site-directed mutagenesis, PCR, and gene synthesis, etc.
[0053] In the present application, the term "codon optimization" generally refers to replacing one or more codons in a parent polypeptide encoding nucleic acid by codons encoding the same amino acid residue with different relative usage frequencies to improve the expression of the nucleic acid encoding the polypeptide. In the present application, as long as the mutation of the amino acid is the same as the present application, all possible codons encoding the mutant amino acid are within the scope of the present application.
[0054] In the present application, the term "trimer" generally refers to a protein structure composed of three protein subunits of the same type or different types, and the protein trimer can be connected together by a special chemical structure. In the present application, the protein trimer can be the F protein of respiratory syncytial virus.
[0055] In the present application, the term "conformational change" generally refers to a change in the spatial structure of a protein molecule. For example, the conformational change may include a change in the chemical bonds in the protein molecule or a change in the folding mode of a polypeptide.
[0056] In the present application, the term "signal peptide" generally refers to an amino acid sequence present at the N-terminus of a transmembrane protein as a signal when it crosses the membrane. For example, the transmembrane protein may include a secretory protein or a cell membrane protein. For example, the signal peptide can be synthesized at the N-terminus of the transmembrane protein in the form of a precursor polypeptide.
[0057] In the present application, the term "structural protein" generally refers to a protein that constitutes a component of a virus particle. The structural protein may include a structural protein of a respiratory syncytial virus. The structural protein described in the present application may include an F protein, a G protein, and a SH protein.
[0058] In the present application, term " before fusion " generally refers to the conformation presented by the structural protein of virus when membrane fusion does not occur before infecting host cell.Generally speaking, before the fusion of wild-type RSV F protein, it is a kind of metastable protein, and its conformation is discontinuous after virus infection host cell and membrane fusion occurs, and progressively and irreversible conformational change becomes the conformation (conformation after fusion) of a low-energy stable state.In the present application, RSV F protein is carried out a series of transformations so that the F protein mutant can stably be in the fusion precursor state.
[0059] In this application, the expression of protein mutation sites is usually expressed as "amino acid + amino acid position + amino acid after mutation". In this application, the mutation may include but is not limited to the addition, replacement, deletion and / or deletion of amino acids. For example, the term "E218C" usually refers to the mutation of glutamic acid (E) at position 218 to cysteine (C).
[0060] In this application, the term "nucleic acid molecule" generally refers to nucleotides of any length in isolated form, either deoxyribonucleotides or ribonucleotides, or analogs isolated from their natural environment or artificially synthesized.
[0061] In the application, the term "vector" refers to a nucleic acid carrier into which a polynucleotide encoding a protein can be inserted and the protein can be expressed. The vector can be transformed, transduced or transfected into the host cell so that the genetic material elements it carries are expressed in the host cell. For example, vectors include: plasmids; phagemids; cosmids; artificial chromosomes such as yeast artificial chromosomes (YAC), bacterial artificial chromosomes (BAC) or P1-derived artificial chromosomes (PAC); bacteriophages such as lambda phage or M13 phage and animal viruses. The types of animal viruses used as vectors include retroviruses (including lentiviruses), adenoviruses, adeno-associated viruses, herpes viruses (such as herpes simplex virus), poxviruses, baculoviruses, papillomaviruses, and papillomaviruses (such as SV40). A vector may contain a variety of elements for controlling expression, including promoter sequences, transcription start sequences, enhancer sequences, selection elements and reporter genes. In addition, the vector may also contain a replication start site. The vector may also include components that assist it to enter cells or assist the target element to be integrated into host cells, such as virus particles, liposomes, protein coats or integrase, but not limited to these substances.
[0062] In the present application, the term "pharmaceutical composition" generally refers to a composition for preventing / treating a disease or illness. The pharmaceutical composition may include RSV F protein mutants described in the present application, nucleic acid molecules described in the present application, carriers described in the present application and / or cells described in the present application, and optionally pharmaceutically acceptable carriers. In addition, the pharmaceutical composition may also include suitable preparations of one or more (pharmaceutically effective) adjuvants, stabilizers, excipients, diluents, solubilizers, surfactants, emulsifiers and / or preservatives. The acceptable components of the composition are usually nontoxic to the recipient at the dosage and concentration used.
[0063] In the present application, the term "pharmaceutically acceptable carrier" generally includes pharmaceutically acceptable carriers, excipients or stabilizers that are non-toxic to cells or mammals exposed thereto at the doses and concentrations employed. Physiologically acceptable carriers may include, for example, buffers, antioxidants, low molecular weight (less than about 10 residues) polypeptides, proteins, hydrophilic polymers, amino acids, monosaccharides, disaccharides and other carbohydrates, chelating agents, sugar alcohols, salt-forming counterions, such as sodium, and / or nonionic surfactants.
[0064] In this application, the term "comprising" generally means including the features specifically stated, but not excluding other elements.
[0065] This application is based on structural biology and combined with immunological principles to design a new protective vaccine with high safety, wide protection and reliable preparation process. The stability of the recombinant protein vaccine provided by this application is significantly improved compared with the publicly reported DS-CavI and Pfizer's patent disclosed preferred molecule 847. The RSV F protein mutant can be stably maintained in a fusion precursor state, and can induce higher neutralizing antibody levels in animal immune tests when used alone or with a suitable adjuvant.
[0066] In the present application, the term "adjuvant" generally refers to any substance that assists or regulates the action of a drug, including but not limited to immunological adjuvants, which enhance the immune response to an antigen or diversify the immune response. In the present application, the adjuvant can be used to enhance the antigenicity of the RSV F protein mutant. In some embodiments, the adjuvant can include a mineral (e.g., alum, aluminum hydroxide, or phosphate) suspension. In some embodiments, the adjuvant can include an oil-in-water emulsion. In some embodiments, the adjuvant can include a liposome. In some embodiments, the adjuvant can include an immunostimulant such as MPL, CpG, Poly:IC.
[0067] In this application, the term "vaccine" refers to a pharmaceutical composition comprising an immunogen capable of eliciting a prophylactic or therapeutic immune response in an individual. Typically, a vaccine elicits an antigen-specific immune response against a pathogen, such as a viral pathogen.
[0068] In the present application, the term "pre-fusion specific antibody" refers to an antibody that specifically binds to the RSV F glycoprotein in the pre-fusion conformation, but does not bind to the RSV F protein in the post-fusion conformation. Exemplary pre-fusion specific antibodies include D25, AM22, 5C4, MPE8 and AM14 antibodies.
[0069] In the present application, in the case of an antibody binding to a given target molecule, the term "specific binding" means that the antibody binds to the target molecule with a higher affinity than it binds to other substances tested. For example, an antibody that specifically binds to the RSV F protein in a prefusion conformation is an antibody that binds to the RSV F protein in a prefusion conformation with a higher affinity than it binds to the RSV F protein in a postfusion conformation.
[0070] In the present application, the term "SC-TM" refers to a form of RSV F protein having the amino acid sequence described in the document "Krarup, A., et al. (2015). "A highly stable prefusion RSV F vaccine derived from structural analysis of the fusion mechanism." Nat Commun 6:8143".
[0071] In this application, the term "847" refers to the pXCS847 molecule in patent CN108738312A.
[0072] In the present application, the term "DS-CavI" is a molecule described in the document "McLellan, JS, et al. (2013). "Structure-based design of a fusion glycoprotein vaccine for respiratory syncytialvirus." Science 342(6158):592-598".
[0073] In the present application, the term "D25" refers to the antibody described in WO 2008 / 147196 A2, which can specifically recognize the F protein of respiratory syncytial virus in the pre-fusion conformation.
[0074] In the present application, the term "AM14" refers to the antibody described in the document "Wayne Harshbarger., et al. (2021) Improved epitope resolution of the prefusion trimer-specific antibody AM14 bound to the RSV F glycoprotein, mAbs, 13: 1, DOI: 10.1080 / 19420862.2021.1955812", which only binds to the respiratory syncytial virus F protein that is trimerized and in the prefusion conformation, and does not bind to the monomeric fusion F protein.
[0075] Without intending to be bound by any theory, the following examples are merely intended to illustrate the RSV F protein mutants, preparation methods, quality characterizations and uses of the present application, and are not intended to limit the scope of the invention of the present application.
[0076] The present invention will be further described below in conjunction with embodiments:
[0077] Example 1: Design and expression of RSV F protein mutants
[0078] The present invention has evaluated more than 400 kinds of RSV F protein mutants in total, and this embodiment summarizes the design and expression of positive control molecules (SC-TM, DS-CavI, 847) and 7 representative RSV F protein mutants (each of which is identified by a unique identifier, such as YK001Ag222, YK001Ag399, etc.). The design and expression of exemplary RSV F mutants are provided in Table 1. 7 representative mutants are each designed and prepared based on the amino acid sequence described in SEQ ID NO.1. The method for expressing and purifying these exemplary RSV F mutants is described in Examples 2 and 4, and the method for determining the expression of RSV F mutants is described in Example 3, and the expression of the RSV F mutant is the target protein content in the cell transient expression supernatant described in Example 2 of the present invention.
[0079] The D25 antibody can specifically recognize the F protein of the respiratory syncytial virus before fusion conformation, while the AM14 antibody can only specifically recognize the trimerized pre-fusion F protein. In order to ensure that the improved designed mutant of the respiratory syncytial virus F protein is in the pre-fusion conformation and in the trimerized state, the binding of the mutant to D25 and AM14 was determined in this example, as shown in Tables 1 and Figure 2As shown in the figure, all 7 representative molecules can specifically bind to the two antibodies, and the expression levels measured by the two antibodies are not much different (less than one-fold), indicating that the 7 representative molecules are similar to the positive control molecule in conformation and can present a pre-fusion trimerization conformation. Among them, the three representative molecules YK001Ag399, YK001Ag401 and YK001Ag404 do not contain heterologous trimerization domains, and successfully replaced heterologous foldon with their own homologous S155-S173 peptide segments without affecting the trimerization of the target protein.
[0080] Table 1. Sequence design and expression levels of exemplary RSV F protein mutants
[0081]
[0082]
[0083] Example 2: Construction of expression vector and small volume expression of RSV F protein mutants
[0084] The nucleic acid sequence encoding the RSV F protein mutant was codon optimized and synthesized using CHO as the host, cloned into the YKVGS001 vector using HindIII and NotI, and the plasmid was extracted for further transfection.
[0085] Expi 293 cells with fast growth and good cell morphology were used as transfection hosts for large-volume transfection. The viable cell density of the seed cells was adjusted to 3 million per milliliter before transfection, and 20 mL of cell solution was used for transfection for each project. Each project used 20 μg of plasmid and 100 μg of PEI MAX transfection reagent, which were diluted with 600 μL of OPM-293CD05 culture medium, mixed gently, and then the diluted transfection reagent was gently added to the diluted plasmid, and incubated at room temperature for 8 minutes to prepare the plasmid complex. After the incubation, the prepared plasmid complex was slowly dripped into the cell solution to be transfected, and the cell solution was placed in a shaker at 37°C and 8% CO2 for culture at a speed of 200 rpm. 18-24 hours after transfection, add 10% culture volume of BalanCD CHO Feed 4 (0.8X) (V / V) to each bottle of transfected cells, and monitor the cell status every day. The transfection cycle is usually 4 days. On the 4th day, the cell culture supernatant is harvested to measure the expression level and transferred to the purification section for purification.
[0086] Example 3: RSV F protein mutation expression and stability determination (detected with monoclonal antibodies D25 and AM14)
[0087] The cell supernatant harvested in Example 2 of the present invention was filtered through a disposable 0.22 μm sterile filter and then packaged. The sample was directly tested for the expression of the target protein in the supernatant or placed in a 60°C constant temperature box for 1 hour to investigate the stability of the sample under high temperature conditions. The gator based on the principle of biomembrane optical interference was used. TM The molecular interaction detector calculates the content of the target protein in the cell expression supernatant and stability test samples by testing the binding rate of RSV fusion precursor-specific recognition monoclonal antibody D25 or AM14 with RSV F mutant.
[0088] The specific test parameters are as follows: after the protein A probe is balanced for 50 seconds, D25 or AM14 monoclonal antibodies are captured, and after 120 seconds of equilibrium, the binding reaction with the cell expression supernatant of the RSV F protein mutant is carried out for 200 seconds, and then a 120-second dissociation reaction is carried out to test the binding of the designed RSV F protein mutant with D25 or AM14 monoclonal antibodies. The content of the target protein is calculated based on the standard curve established based on the standard sample with known concentration.
[0089] In some embodiments, the expression level of the selected RSV F protein mutants is measured as shown in Tables 1 and Figure 2 The stability test results are shown in Table 2. Figure 3 As shown, after the improved design described in the present invention, most RSV F protein mutants can stably present the fusion precursor conformation. After being placed at 60°C for 1 hour, preferred RSV F protein mutants such as YK001Ag403, YK001Ag404, and YK001Ag399 can still maintain a high binding activity with D25 monoclonal antibody and AM14.
[0090] Table 2 Stability study of exemplary RSV F protein mutants
[0091]
[0092] By comparing the stability data of YK001Ag400 and YK001Ag401, YK001Ag402 and YK001Ag404, and YK001Ag403 and YK001Ag399, it can be seen that under the premise that the designs of other mutations except the C-terminus are the same (the K508C-S509C mutations are adjacent to the C-terminus and are included in the C-terminus design to increase the interaction between the C-terminal trimers), replacing the heterologous foldon with its own homologous S155-S173 peptide segment does not affect the trimerization and stability of the target protein.
[0093] By comparing the stability data of YK001Ag400 and YK001Ag402, and YK001Ag401 and YK001Ag404, it can be seen that under the premise that the other mutation designs are the same, the introduction of A74C-E218C mutation can greatly increase the stability of the trimer before fusion of the target protein.
[0094] By comparing the stability data of YK001Ag401 and YK001Ag399, and YK001Ag400 and YK001Ag403, it can be seen that under the premise that the other mutation designs are the same, the introduction of Q279C-A241C mutation can also significantly increase the stability of the trimer before fusion of the target protein.
[0095] Comparing the expression and stability data of YK001Ag222 and YK001Ag400, it can be seen that the introduction of E60L mutation can improve protein expression and stability to a certain extent under the premise that the other mutation designs are the same.
[0096] Example 4: Purification of RSV F protein mutants
[0097] 1. Use 0.5M NaOH to adjust the pH of the clarified harvest solution to 7.0, and use 20mM PB pH 7.0 buffer to adjust the conductivity to no more than 8.0mS / cm;
[0098] 2: Load the pretreated sample onto a strong cation exchange chromatography column pre-equilibrated with 20 mM PB pH 7.0 buffer. After loading, perform gradient elution with 20 mM PB pH 7.0, 1 M NaCl buffer, and collect the eluate containing the target protein component;
[0099] 3: Adjust the pH of the strong cation exchange chromatography eluate to 7.5 using 0.5 M NaOH;
[0100] 4: After sample treatment, load the sample onto a composite mode chromatography column pre-equilibrated with 20 mM PB pH 7.5 buffer. After loading, perform gradient elution with 20 mM PB pH 7.5, 1 M NaCl buffer, and collect the eluate containing the target protein component;
[0101] 5: Load the composite mode chromatography eluate onto a size exclusion chromatography column pre-equilibrated with 1xPBS pH 7.4, and collect the eluate containing the target protein component, which is the prepared high-purity protein sample.
[0102] The purification results of the selected representative RSV F mutant YK001Ag399 are shown in Figure 4As shown, after purification, the target protein with high electrophoretic purity can be obtained, and the trimer conformation of the F protein can be maintained. In the present invention, taking the representative RSV F mutant YK001Ag399 as an example, the feline protease cleavage site introduced thereon is deleted in order to maintain the pre-fusion conformation of the F protein, and the introduction of other mutations is to enhance the stability of the protein; and the C-terminal design thereof uses a fragment of the soluble expression region of the F protein itself to replace the C-terminal transmembrane insoluble region of the F protein, which can play a role in maintaining the trimer conformation of the F protein.
[0103] Example 5: Particle size distribution analysis of selected pre-fusion RSV F mutants
[0104] In order to analyze the size distribution of the designed RSV F protein mutants, this experiment used the SEC-HPLC method to analyze the purified samples. The specific implementation method is: the chromatographic column is Agilent Bio SEC-3 (3μm, 4.6*300mm), detection wavelength is 280nm, mobile phase is 1×PBS, flow rate is 0.4ml / min, injection volume is 10μl, isocratic elution is 15min. The preparation of the test solution is as follows: take 50μl sample in a 1.5ml centrifuge tube, centrifuge at 10000rpm for 1min, take the supernatant into a liquid phase vial containing an inner insert tube, and set aside. The protein is eluted and separated according to the molecular size of the component to be tested.
[0105] The molecular weight of the RSV F mutant monomer of the present invention is about 53KDa. Figure 5 As shown, the peak retention time of the selected RSV F mutant is close to that of γ-globulin with a molecular weight of 158 KDa, confirming that the RSV F mutant of the present invention is a trimer conformation.
[0106] Example 6: Structural thermal stability of selected pre-fusion RSV F protein mutants
[0107] In order to investigate the thermodynamic stability of the designed RSV F protein mutants, this experiment evaluated the particle size and thermal denaturation of the antigen by Prometheus Panta. The specific implementation method is: take 50 μl of the test sample, centrifuge at 8°C 15000g for 10 minutes, load it into a capillary (manufacturer: Nano Temper, item number: PR-C002), load it into the tray, each test sample has 3 replicates, select the Thermal Unfolding module in the equipment software, start temperature 25°C, end temperature 95°C, and heat up at a rate of 1°C / min for temperature rise detection.
[0108] The results of the investigation of the structural thermal stability of representative RSV F protein mutants are shown in Table 3. The Tm value of the YK001Ag399 molecule is significantly higher than that of the SC-TM and DS-CavI positive control molecules, and is similar to that of the pXCS847 molecule, proving that the improved designed protein has excellent structural thermal stability.
[0109] Table 3. Structural stability data of exemplary RSV protein mutants
[0110]
[0111] * represents the mean, σ* represents the variance, and NA represents data abnormality that cannot be fitted.
[0112] Example 7: Improved RSV F protein mutant immune response in mice
[0113] In order to study the immunogenicity of the RSV F protein mutant provided by the present invention, the inventors of the present invention prepared a vaccine composition (0.5 ml / dose) containing different adjuvants and taking the representative designed molecule YK001Ag399 as the antigen. The group information is specifically shown in Table 4. The immunogenicity of each group of vaccine compositions was investigated in SPF female 6-8 week old BALB / c mice, with 6 mice in each group, for a total of 3 groups. The immunization method was intramuscular injection, and the injection volume was 50 μl / dose / mouse (1 / 10 of the intended human dose). Each mouse was immunized twice, with an immunization interval of 3 weeks. Blood was collected from each group of mice two weeks after the second immunization, and the IgG antibody titer against the F protein in the serum was detected by ELISA ( Figure 6 -A); Three weeks after the second immunization, blood was collected from each group of mice, and the serum neutralizing antibody titer was detected by neutralization experiments based on wild-type A and B live viruses ( Figure 6 -B / C).
[0114] Table 4 Different RSV vaccine composition formulations
[0115] Group Dosage / 0.5ml 1 solvent 2 60 μg YK001Ag399 protein, AS01 adjuvant 3 60μg YK001Ag399 protein, 250μg CpG, 500μg aluminum adjuvant
[0116] Compared with the vehicle control group (Group 1), high levels of binding antibodies against the F protein were detected in the sera of mice in each experimental group two weeks after the second immunization, and the sera of mice in each experimental group three weeks after the second immunization were able to effectively neutralize the replication of type A and type B wild-type live viruses in in vitro cells, indicating that the RSV F protein mutant provided by the present invention has excellent immunogenicity, and when used as a vaccine product, it can induce cross-protection against both A / B strains.
[0117] The above are only preferred embodiments of the present invention and are not intended to limit the present invention. It should be pointed out that a person skilled in the art can make several improvements and modifications without departing from the technical principles of the present invention, and these improvements and modifications should also be regarded as within the scope of protection of the present invention.
Claims
1. An improved respiratory syncytial virus fusion F protein mutant, characterized in that: The mutant uses a segment of the soluble expression region of the respiratory syncytial virus fusion F protein itself to replace the C-terminal transmembrane insoluble region of the respiratory syncytial virus fusion F protein; the segment of the soluble expression region of the respiratory syncytial virus fusion F protein itself is a structurally rigid segment; the mutant also includes deleting a segment containing a ferin protease cleavage site in the amino acid sequence of the respiratory syncytial virus fusion F protein; The amino acid sequence of the respiratory syncytial virus fusion F protein is shown in SEQ ID NO.1, and a fragment of the soluble expression region of the respiratory syncytial virus fusion F protein itself is an amino acid sequence fragment from positions 155 to 173, an amino acid sequence fragment from positions 190 to 204, or an amino acid sequence fragment from positions 255 to 275 of the amino acid sequence shown in SEQ ID NO.1; The C-terminal transmembrane insoluble region of the respiratory syncytial virus fusion F protein is the amino acid fragment at position 510 and thereafter of the amino acid sequence shown in SEQ ID NO.1; When performing the replacement of the amino acid fragment at position 510 and thereafter, it also includes mutating the lysine at position 508 and the serine at position 509 to cysteine.
2. The respiratory syncytial virus fusion F protein mutant according to claim 1, characterized in that The mutant further comprises at least one disulfide bond mutation.
3. The respiratory syncytial virus fusion F protein mutant according to claim 2, characterized in that: The mutant is obtained by subjecting the amino acid sequence of SEQ ID NO.1 to at least one of the following mutations: Mutate alanine at position 74 and glutamic acid at position 218 to cysteine; The glutamine at position 279 and the alanine at position 241 were mutated to cysteine.
4. The respiratory syncytial virus fusion F protein mutant according to claim 1, characterized in that The mutant also includes mutating one or more charged amino acids in the amino acid sequence of the respiratory syncytial virus fusion F protein into polar amino acids, hydrophobic amino acids or aromatic amino acids to release the electrostatic repulsion in the RSV F protein and enhance the stability of the RSV F pre-fusion protein.
5. The respiratory syncytial virus fusion F protein mutant according to claim 4, characterized in that: The mutant is obtained by subjecting the amino acid sequence of SEQ ID NO.1 to at least one of the following mutations: The glutamic acid at position 60 was mutated to alanine, glycine, serine, threonine, leucine, methionine or phenylalanine.
6. The respiratory syncytial virus fusion F protein mutant according to claim 1, characterized in that: The fragment containing the feline protease cleavage site is 28 to 46 amino acids between the 100th and 147th positions in the amino acid sequence shown in SEQ ID NO.
1.
7. A nucleic acid molecule encoding the respiratory syncytial virus fusion F protein mutant according to any one of claims 1 to 6.
8. A carrier, characterized in that The vector comprises the nucleic acid molecule of claim 7.
9. A cell, characterized in that The cell expresses the respiratory syncytial virus fusion F protein mutant according to any one of claims 1 to 6, or contains the nucleic acid molecule according to claim 7, or contains the vector according to claim 8.
10. A vaccine, characterized in that The vaccine comprises the respiratory syncytial virus fusion F protein mutant according to any one of claims 1 to 6.
11. A pharmaceutical composition, characterized in that The pharmaceutical composition comprises the respiratory syncytial virus fusion F protein mutant according to any one of claims 1 to 6, the vaccine according to claim 10, the nucleic acid molecule according to claim 7 or the vector according to claim 8.
12. Use of the respiratory syncytial virus fusion F protein mutant according to any one of claims 1 to 6, the nucleic acid molecule according to claim 7, the vector according to claim 8, the cell according to claim 9, the vaccine according to claim 10 or the pharmaceutical composition according to claim 11 in the preparation of products for detecting, preventing and / or treating respiratory syncytial virus infection.
Citation Information
Patent Citations
RSV f protein mutants
CN108738312A
RSV-specific binding molecules and means for producing them
WO2008147196A2
Respiratory syncytial virus pre-fusion F protein and application thereof
CN110054668A
Respiratory syncytial virus pre-fusion F protein mutant and application thereof
CN116003536A
Mutant respiratory syncytial virus pre-fusion F protein and application thereof
CN116284266A
